Abstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that is secreted by cells of the lower gastro-intestinal tract following ingestion of a carbohydrate - or fat-containing meal. GLP-1 has multiple sites of action — it increases pancreatic responsiveness to high glucose, delays gastric emptying, reduces appetite and food intake which altogether results in improved glycemic control and weight reduction. However, in vivo native GLP-1 is rapidly degraded and therefore of limited value for diabetes therapy. AVE0010 is a new synthetic GLP-1 receptor agonist with extended biological activity being developed for the treatment of patients with type 2 diabetes mellitus (T2DM). The effects of AVE0010 in some preclinical pharmacology studies are provided below.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
